Welcome to Paid Research Studies.


Browse Locations ... United States» ... Minnesota» ... Burnsville






  • Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

    Conditions:   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
    Interventions:   Drug: lapatinib ditosylate;   Radiation: whole-brain radiation therapy
    Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
    Recruiting - verified March 2013
  • Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

    Conditions:   Light Chain Deposition Disease;   Smoldering Multiple Myeloma
    Interventions:   Other: clinical observation;   Drug: lenalidomide;   Other: laboratory biomarker analysis
    Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
    Recruiting - verified May 2013
  • Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

    Conditions:   Recurrent Uterine Sarcoma;   Stage IIIA Uterine Sarcoma;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Leiomyosarcoma
    Interventions:   Other: placebo;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim
    Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
    Recruiting - verified May 2013
  • Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

    Conditions:   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
    Interventions:   Drug: temsirolimus;   Biological: bevacizumab
    Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
    Recruiting - verified June 2013
  • Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

    Conditions:   Breast Cancer;   Cardiac Toxicity
    Interventions:   Drug: Coreg CR®;   Drug: lisinopril;   Other: placebo
    Sponsors:   University of South Florida;   University of South Florida;   National Cancer Institute (NCI)
    Recruiting - verified January 2013
  • Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

    Condition:   Lung Cancer
    Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Drug: etoposide
    Sponsors:   Alliance for Clinical Oncology Trials;   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Eastern Cooperative Oncology Group;   North Central Cancer Treatment Group;   Southwestern Oncology Group (SWOG)
    Recruiting - verified June 2013
  • Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
    Recruiting - verified June 2013
Main Menu
Clinical Trial Locations
Clinical Trial Categories